Patents by Inventor Adegoke ADENIJI

Adegoke ADENIJI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-BETA-NAPHTHYL-ACETIC ACID ANALOGS AS AKR1C3 INHIBITORS AND METHODS OF USING SAME
    Publication number: 20230039244
    Abstract: The invention includes 2-?-naphthyl-acetic acid derivatives, which are selective AKR1C3 inhibitors. In certain embodiments, the compounds of the invention are R-naproxen analogs. The invention further includes methods of treating cancer, such as prostate cancer and/or castration-resistant prostate cancer, using at least one compound of the invention.
    Type: Application
    Filed: September 15, 2022
    Publication date: February 9, 2023
    Inventors: Trevor M. PENNING, Adegoke ADENIJI, Lawrence J. MARNETT
  • 2-beta-naphthyl-acetic acid analogs as AKR1C3 inhibitors and methods of using same
    Patent number: 11459295
    Abstract: The invention includes 2-?-naphthyl-acetic acid derivatives, which are selective AKR1C3 inhibitors. In certain embodiments, the compounds of the invention are (R)-naproxen analogs. The invention further includes methods of treating cancer, such as prostate cancer and/or castration-resistant prostate cancer, using at least one compound of the invention.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: October 4, 2022
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, VANDERBILT UNIVERSITY
    Inventors: Trevor M. Penning, Adegoke Adeniji, Lawrence J. Marnett
  • 2-BETA-NAPHTHYL-ACETIC ACID ANALOGS AS AKR1C3 INHIBITORS AND METHODS OF USING SAME
    Publication number: 20180305305
    Abstract: The invention includes 2-?-naphthyl-acetic acid derivatives, which are selective AKR1C3 inhibitors. In certain embodiments, the compounds of the invention are (R)-naproxen analogs. The invention further includes methods of treating cancer, such as prostate cancer and/or castration-resistant prostate cancer, using at least one compound of the invention.
    Type: Application
    Filed: October 21, 2016
    Publication date: October 25, 2018
    Inventors: Trevor M. PENNING, Adegoke ADENIJI, Lawrence J. MARNETT